Loading
Every dated change on the records linked to Cervical cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025
A milestone in how this cancer is treated.
First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy
Recurrent or metastatic cervical cancer after platinum chemotherapy
OS HR 0.
Simple hysterectomy was non-inferior to radical hysterectomy for three-year pelvic recurrence in low-risk early cervical cancer, with fewer urinary complications.
A milestone in how this cancer is treated.
OS 32.
Durvalumab added to chemoradiotherapy did not significantly improve progression-free survival in locally advanced cervical cancer.
Endometrial ORR 57.
OS 11.
5-year OS 80% vs 72% (HR 0.
PFS HR 0.
Four practice-changing phase 3 results presented at ESMO 2023.
Recurrent/metastatic cervical cancer after platinum
Single-dose efficacy 97.
A milestone in how this cancer is treated.
Recurrent/metastatic cervical cancer after chemotherapy (full 2024)
OS 12.
Efficacy against persistent HPV 16/18 infection: 95.
OS 26.
5-year OS 72% vs 71%; no benefit.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Neoadjuvant nivolumab produced pathological complete responses in a substantial share of resectable Merkel cell carcinomas, with durable responses; nivolumab also showed activity in recurrent cervical cancer.
Biliary cohort ORR 5.
Swedish registry study shows ~88% cancer reduction in women vaccinated before 17.
Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy
Cervical cancer mortality rate ratio 0.
A milestone in how this cancer is treated.
Prevention of cervical cancer and precursor lesions caused by HPV 16 and 18 in females 10 to 25 (discontinued in the US 2016)
Cervical cancer deaths HR 0.
Vaccine efficacy against CIN2+ associated with HPV-16/18 92.
NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC
Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later
Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by Gardasil 9
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.